T David Koster, Pallav L Shah, Arschang Valipour, Gerard J Criner, Felix J F Herth, Richard Sue, Douglas K Hogarth, Ralitza T Martin, Amit K Mahajan, Raed Alalawi, Lisa Kopas, Avi Cohen, Douglas E Wood, Jonathan Kurman, Narinder S Shargill, Mark Dransfield, Dirk-Jan Slebos, Michael Perch
Bronchoscopic lung volume reduction treatment with Zephyr one-way valves is an effective guideline-based treatment option for patients with severe emphysema and hyperinflation. However, in some cases the treatment response is less than anticipated or there might be a loss of initial treatment effect. Reasons for the lack of response can include incorrect assessment of collateral ventilation, improper valve placement, or patient related factors. Loss of initial benefit can be due to granulation tissue formation and subsequent valve dysfunction, or there may be side effects such as excessive coughing or infectious problems...
April 18, 2024: Respiratory Medicine